KV Pharmaceutical Co.(fka KVPHQ)

[mkinhaw]

No assurance commons will survive

http://www.kvph.com/RESTRUCTURING/PDFs/KV_Shareholder_FAQ.pdf

from the co s website

MK

[mkinhaw]

Hard to tell, made a new lo today
but the pricr looks like there s no recovery
for commons
I have it on watch

MK

[ErnieBilco]

Will they be on sale tomorrow??? Or has it already been baked in?

[mkinhaw]

KVPHQ tomorrow

http://www.otcbb.com/asp/dailylist_detail.asp?d=08/07/2012&mkt_ctg=NON-OTCBB

MK

[mkinhaw]

KVPHA new symbol .08 last
ch 11 too

MK

[surf1944]

8:00AM K-V Pharma announces planned transition of trading of Class A and Class B common shares to the OTC markets (KV.A) 0.32 : Co announced that its Class A and Class B common shares may be traded in the over the counter market following the Company's suspension from the NYSE. However, K-V cannot ensure that either class of stock will be, or will continue to be, traded. Trading in the OTC market may result in significantly lower trading volumes and liquidity for investors seeking to buy or sell shares of K-V's common stock.

[1millman]

I think she may have seen bottom. Strong support these past couple of days at .48 to .52. That was quite a blood bath KV.A had since the 18th.

[$King]

KV.A .99 LOD

[$King]

KV.A @ 1.32

[KING_TRADER$]

yeah. horrible blood bath for KV.A I'm out for this stock! f this shiet!

[slawmd27]

http://www.bizjournals.com/stlouis/news/2012/02/10/kv-pharmaceuticals-q4-loss-more-than.html?ana=yfcpc

[KING_TRADER$]

any new news for kv pharm?

[tgler]

boooom

[MakinBank]

what does that mean?

[Superfly15]

Should be a bounce coming sometime with tax selling season ending in the next week or two.

[PETERDENIEL2003]

UPDATE:New Makena Injection Policy - COVERED FOR REIMBURSEMENT..


https://www.forwardhealth.wi.gov/kw/pdf/2011-69.pdf

[$King]

KV.A LOD 1.15

[$tockfather]

Happy i was able to sell @ $1.75 this morning. Didn't like the gap down this AM, will wait for this to settle down a little before rebuying

[Blade$dream]

sorry for the late reaction....

http://www.businessweek.com/news/2011-11-08/kv-rises-after-fda-says-to-probe-drug-compounding-pharmacies.html

[$King]

KV.A @ 1.71

[Superfly15]

This is why it flew today FYI. FDA is doing a test to see if K-V's claims that Makena is safer than compounded is true. If validated, stock probably to the moon. If not, K-V is dead for sure.

FDA Statement on Makena

SILVER SPRING, Md., Nov. 8, 2011 /PRNewswire-USNewswire/ -- FDA approved Makena (hydroxyprogesterone caproate) in February 2011 for the reduction of the risk of certain preterm births in women who have had at least one prior preterm birth. For many years before Makena was approved, a version of the active ingredient of Makena has been available to patients whose physicians requested the drug from a pharmacist who compounded the drug. In March 2011, after learning that the owner of Makena, K-V Pharmaceuticals, had sent letters to pharmacists indicating that FDA will no longer exercise enforcement discretion with regard to compounded versions of Makena, FDA issued a statement about compounded hydroxyprogesterone caproate to clarify the agency's enforcement priorities. In the March 2011 statement, FDA explained that the agency prioritizes enforcement actions related to compounded drugs using a risk-based approach, giving the highest enforcement priority to pharmacies that compound products that are causing harm or that amount to health fraud. The agency also stated:

In order to support access to this important drug, at this time and under this unique situation, FDA does not intend to take enforcement action against pharmacies that compound hydroxyprogesterone caproate based on a valid prescription for an individually identified patient unless the compounded products are unsafe, of substandard quality, or are not being compounded in accordance with appropriate standards for compounding sterile products. As always, FDA may at any time revisit a decision to exercise enforcement discretion.

In October 2011, FDA received information from K-V Pharmaceuticals regarding the potency and purity of samples of bulk hydroxyprogesterone caproate active pharmaceutical ingredients (APIs) and compounded hydroxyprogesterone caproate products. According to the analysis of this information provided by K-V, there is variability in the purity and potency of both the bulk APIs and compounded hydroxyprogesterone caproate products that were tested. Although FDA has not validated or otherwise confirmed the analyses provided by K-V, FDA has carefully reviewed the data and will conduct an on-site review of the laboratory analyses.

FDA has begun its own sampling and analysis of compounded hydroxyprogesterone caproate products and the bulk APIs used to make them. That process is ongoing. In the meantime, we remind physicians and patients that before approving the Makena new drug application, FDA reviewed manufacturing information, such as the source of the API used by its manufacturer, proposed manufacturing processes, and the firm's adherence to current good manufacturing practice. Therefore, as with other approved drugs, greater assurance of safety and effectiveness is generally provided by the approved product than by a compounded product.
Media Inquiries: Shelly Burgess, 301-796-4651, [e-mail]

[power_forward]

you didn't see the news?? check the link on the Bounce(Boing) board, posted by momentum74

[$tockfather]

Bought in EOD @ $1.70...... Something BIG must have leaked. Huge buys in the last hour. Most of the daily trading volume came in the last hour on record volume in the last 6 months. Lets see what tomorrow brings

[$tockfather]

What's the reason for the spike up in powerhour today???

[Blade$dream]

finaly some movement over here....gogogogog

[Superfly15]

Just a PR, nothing really new. They are getting desperate.

[lemm]

traiding is not stopped still going on in the richt directery

[jayvicc]

WHY is KV/A trading halted??

[jayvicc]

KV/A is BACK!!!! WOOO

[lemm]

GOOD NEWS let us go to the moon
go go go KV-A

[QualityStocks]

KV-A Video Chart 9/19/11

http://www.qualitystocks.net/videocharts

KV Pharmaceutical Co. is not a current client of QualityStocks

[mlkrborn]

sold its generic drug unit ;
KV Pharmaceutical wraps $60 million generics unit sale to Zydus
St. Louis Business Journal
Date: Monday, August 8, 2011, 5:36pm CDT
Related:
Manufacturing, Health Care
Enlarge Image
KV Pharmaceutical wraps $60 million generics unit sale to Zydus

Click here to find out more!
Related News

* KV to sell generics unit to Zydus for $60M
* KV loss narrows in fiscal ‘11
* KV, Savvis stocks lead first-quarter rebound
* KV shares slide after FDA announcement
* KV shares up on drug launch news

KV Pharmaceutical Co. KV Pharmaceutical Co. Latest from The Business Journals KV to sell generics unit to Zydus for MKV loss narrows in fiscal ‘11KV, Savvis stocks lead first-quarter rebound Follow this company said Monday it completed the $60 million sale of its generic drug unit, Nesher Pharmaceuticals, to Zydus Pharmaceuticals Inc. and Zynesher Pharmaceuticals.

The deal was first announced in June.

The sale includes manufacturing, packaging and laboratory facilities, intellectual property, existing and future product opportunities, as well as equipment.

Zydus is a unit of India-based drug maker Cadila Healthcare. The deal lets Cadila’s Zydus manufacture and distribute generic controlled substances in the U.S. Nesher reportedly has eight filings with federal drug regulators and five products under development.

“The net proceeds from the transaction will strengthen our financial position and liquidity, while exiting the generics business will immediately reduce our quarterly cash outlays,” KV CEO Greg Divis said. “Moving forward, we will continue working towards making important progress with Makena (the company’s anti-preterm labor drug), returning our branded anti-infective products back to market and supporting additional growth potential for Evamist (hot flash treatment).”

Bridgeton-based KV said the sale of its generic unit has been an “important goal” of the company’s board and management, and in keeping with its strategy of becoming a branded specialty pharmaceutical company focused on women’s health.

The company’s switch in strategy came after KV agreed in February 2010 to pay $27.6 million in fines and restitution to resolve a federal investigation into the company, which halted production and recalled drugs in 2008 after making oversized painkiller tablets. KV ceased operations of Ethex Corp. Ethex Corp. Latest from The Business Journals KV to sell generics unit to Zydus for MKV loss narrows in fiscal ‘11KV Pharmaceutical to sell M in shares Follow this company , its old generic/nonbranded pharmaceutical operations, in March 2010 and dissolved Ethex in December 2010.

KV then formed Nesher last year to operate as the sales and marketing company for KV’s generic products.

KV also said Monday it has entered into a supply agreement with Zydus to provide third-party manufacturing services for Clindesse and Gynazole-1, which are vaginal creams.

For fiscal 2011 ended March 31, KV Pharmaceutical (NYSE: KV-a, KV-b) reported a loss of $174 million on revenue of $27.3 million.

[mlkrborn]

KV-A $1.25 Why Did My Stock Just Die?

By Rich Duprey | More Articles
August 12, 2011 | Comments (1)
Baby blues
Specialty pharmaceutical KV Pharmaceuticals filed its quarterly report the other day, and the drain on its business that its overpriced drug Makena represents was still apparent.

To recap, KV outraged just about everyone earlier this year, when it announced a pricing scheme for the drug that made it look as if it was trying to profit off at-risk babies. To quell the uproar, KV first offered financial assistance to those who couldn't afford the $1,500-per-dose cost and then cut the price to $690 when that did little to mollify anyone.

The FDA then weighed in and said it wouldn't grant Makena exclusivity, meaning the original lower-cost options would still be available. The PR disaster was reflected in KV's quarterly results. Revenues were only 2% higher than a year ago, when it had no Makena sales, and it's shipped only 200 more vials than it did when it reported full-year results. It did note, though, that shipments per week rose 39% to 160 vials, compared with the 115 per week it recorded in the first weeks after the drug was launched.

High-priced drugs are sinking a number of pharmaceutical stocks these days, including Dendreon (Nasdaq: DNDN ) , which found it was unable to overcome the "buy-and-bill" method of reimbursement from Medicare. With doctors having to shell out $93,000 for Provenge first, with no guarantee of getting the money back, sales have been lackluster to say the least.

While I'm a little surprised that 93% of the CAPS members rating KV still think it will outperform the broad market averages, its low, two-star rating suggests that they also believe there's better places for your money. You can follow along on KV's progress by adding it to your watchlist, and let us know on the KV Pharmaceuticals CAPS page whether you think investors can afford to wait for sales to take off.
http://www.fool.com/investing/general/2011/08/12/why-did-my-stock-just-die.aspx

[mlkrborn]

u r a liar!

[Superfly15]

CEO said on earnings CC this week that they plan on returning more of their products to market by the end of calender year 2011...something positive to hear.

[alumin]

March of Dimes president,Dr. Jennifer Howse Ph.D., makes $641,000 a year. Do you think she is the person to be discussing price point (considering the median household income in the U.S. is about $44,000)?

[alumin]

MARCH OF DIMES PRESIDENT MAKES 641 000$ per year ....salary alone

[PETERDENIEL2003]

MOST LIKELY WE ARE GETTING DOUBLE FIGURE IN NEAR FUTURE


http://www.benzinga.com/news/rumors/11/06/1197841/kv-a-pharma-receiving-positive-mention-on-turnaround-of-the-company?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29

[Gonzo10000]

Dear Mr. Gonzo10000,

Thank you for your thoughtful message regarding approval by the Food and Drug Administration (FDA) of the drug Makena. I appreciate hearing from you.

As you may know, Makena was approved by the FDA in February, 2011. Makena helps reduce the risk of preterm births for women who have experienced at least one previous preterm birth. Prior to Makena’s approval, the same progesterone treatment was widely available through compounding pharmacies for $10-20 per dose. Once Makena was approved, KV Pharmaceuticals, the manufacturer of the drug, charged $1,500 per dose.

I was very concerned about the steep increase in the price of this important medical treatment and worked with my colleagues on the Senate Health, Education, Labor and Pensions Committee to send a letter to KV Pharmaceuticals urging an immediate lowering of the price. KV Pharmaceuticals has since dropped the price to $690 per dose and while this reduction is a good first step, the price of Makena remains excessive.

Currently, KV Pharmaceuticals has the exclusive rights to produce Makena under the Orphan Drug Act. I believe that KV Pharmaceuticals has gravely abused its privileges under the law. By charging an exorbitant price for this drug, KV Pharmaceuticals does not allow Makena to be accessible to all pregnant women. I am pleased that the FDA has announced that it will continue to permit pharmacists to dispense a less expensive compounded version of Makena for patients with physician approval.

Consumers’ rights are of the utmost importance to me and as I serve in the Senate, I will continue to fight to ensure that Americans have access to the medicines they rely on.

Thank you again for contacting me. Please contact me in the future with any additional questions or concerns you may have.


Sincerely,

Richard Blumenthal
United States Senate

[Blade$dream]

actualy I do not care...because I'm focused now on my other investments....because these 1000 shares are free shares....if they are $2 okay for me....when they go back to 5 or even higher its more then okay for me !!!

Jefferies during CC said some things I liked anyway....KVA is expecting to make some profits not just break even etc...the goals of Jefferies and the management....must go in real numbers...when they do...$2 or $2,5 is a big risk reward IMO

[TaxiCaT]

What was discussed at the meeting and did you read the 10k?

[Blade$dream]

back to $2 !!!! glad I sold most of my shares much much higher....but I do not sell my last 1000pieces....who knows....

[Blade$dream]

back to 5-10USD this year go go go......

[TaxiCaT]

Doing well today - consolidating very nicely -

[Blade$dream]

GO GO GO KVA...................

[Blade$dream]

keep on going this time little puppy.....

[TaxiCaT]

Mini shake out in the AM but this looks like a beast today -

[Blade$dream]

my last free 1000 pieces back to life.....lolllllllll

[air1]

www.biomedtracker.com/

[Superfly15]

Link please?